Authors

Journal

Year

Stage

Setting*

No.

Survival (%) 3Y   5Y

MST **(M)

Bosset, et al. [53]

N Engl J Med

1997

I–III

S CRT+S

139 138

- -

- -

18.6 18.6

Kelsen, et al. [54]

N Engl J Med

1998

I–III

S CT+S

234 233

26 23

- -

16.1 14.9

MRCOCWG* [55]

Lancet

2002

Resectable

S CT+S

437 434

- -

- -

13.3 16.8

Ando et al. [22]

J ClinOncol

2003

II–III Non T4

S S+CT

122 120

- -

52 61

- -

Burmeister, et al. [56]

Lancet Oncol

2005

I–III Non T4

S CRT+S

128 128

- -

- -

19.3 22.2

Stahl, et al. [16]

J ClinOncol

2005

T3-4N0-1 M0

CRT+S dCRT

86 86

31.3 24.4

- -

16.4 14.9

Bedonne, et al. [17]

J ClinOncol

2007

II-III CRT Responder

CRT+S dCRT

129 130

- -

- -

17.7 19.3

Kelsen et al.[57]

J ClinOncol

2007

I–III

S CT+S

234 233

- -

- -

15.6 15.6

Allum et al. [58]

J ClinOncol

2009

Resectable

S CT+S

402 400

- -

17.1 23.0

- -

Ando et al. [23]

Ann SurgOncol

2011

II–III

CT+S S+CT

164 166

- -

55 43

- -

Ozawa, et al. [59]

Esophagus

2012

0 I IIA IIB III IV

Registry

25 363 297 319 655 41

91.3 86.4 62.0 54.0 34.2 6.9

85.9 79.1 55.8 41.8 27.7 -

- - - - - -